RJ Hamster
Biggest whale in Digital Currency is buying 2 tonnes…
Tether is the biggest whale in the crypto space. They’re best known for their stablecoin, USDT.
This company has a license to print US dollars – literally. But that’s not all…
The GENIUS Act is like a blessing from the US monetary authorities to continue their little money printing operation for as long as they like. Why?
Because Tether backs its stablecoin with US Treasuries – the same US Treasuries that other governments are dumping in favor of gold.
And what is Tether doing with all the profits they make by earning interest on US Treasuries?
Buying gold. Lots of it. Roughly two tonnes a week!
I recently met with Tether’s head of special projects – the man behind Tether’s new tokenized gold offering…
What he said shocked even me, a 20+ year veteran in the gold markets.
He told me he expects Tether Gold (XAUt) will soon be bigger than Tether’s roughly $200 billion stablecoin.
Just think what that means for the price of gold as Tether continues accumulating two tonnes a week… more than 100 tonnes a year.
There is one time in the historical cycle when you cannot be without gold. That time is here, now.
Regards,
Garrett Goggin, CFA, CMT
Lead Analyst and Founder, Golden Portfolio
P.S.
I’ve even teamed up with my longtime friend, Porter Stansberry, on this story. Why? Because Porter has been on top of the coming dollar devaluation for over 15 years. He wrote about it in his famous End of America documentary. Porter and I think identically about what’s happening. That’s why Porter’s team put together a special report on the one non-gold asset you MUST have for the coming shift in the world’s monetary system. Go here for details
Wednesday’s Exclusive Story
AbbVie Call Options Spike 2,599%: Tracking the Big Bet
By Jeffrey Neal Johnson. Article Published: 1/16/2026.
Key Points
- Institutional investors are showing high confidence, as evidenced by a significant increase in bullish market activity ahead of financial results.
- The strategic expansion into the metabolic health and obesity markets provides a long-term pathway to diversify the total revenue stream.
- A comprehensive, voluntary federal agreement helps ensure the organization can focus on research and domestic manufacturing with great certainty.
Unusual market activity is often the first sign that big changes are coming to a stock. Professional traders and large institutions frequently use the options market to place high-conviction bets before major news becomes public. On Jan. 15, 2026, AbbVie Inc. (NYSE: ABBV) experienced one of these events: daily call option volume for the healthcare giant surged to 2,599% of its historical average. That spike in bullish activity suggests the smart money is positioning for a significant move. With the stock trading near $216.66, traders appear to be anticipating a breakthrough or a positive financial surprise.
Traders use call options to profit from a rising stock price. When volume spikes by more than 2,500%, it rarely happens by accident. Institutional investors often have access to deep research and sophisticated models that help them anticipate market shifts. By looking at the upcoming calendar, several likely catalysts for this rush of capital into AbbVie become apparent.
Betting on a February Beat: The Q4 Earnings Window
Wall Street ‘Sleeper Stock’ Could Become #1 Stock of 2026 (Ad)
Wall Street veteran reveals #1 investment trend of 2026 (not AI)
Will you potentially make money or lose money in the U.S. stock market in 2026? According to the 50-year Wall Street legend who invented one of Wall Street’s most popular buying and selling indicators – the answer has nothing to do with AI, quantum computing, or cryptos. Instead, it all comes down to the #1 stock he recommends you BUY now…And the #1 stock he recommends you SELL now.
The most immediate reason for the surge in options is the upcoming fourth-quarter 2025 earnings report, expected on Feb. 4, 2026. Institutional confidence is high because the company posted a string of strong quarters in 2025: in every quarter the company beat analyst estimates and raised its full-year guidance. AbbVie currently expects adjusted earnings per share (EPS) of $10.61 to $10.65 for the full year.
Investors have been encouraged by how management handled product transitions that once worried the market. Despite the decline of the blockbuster drug Humira, recent results indicate the company’s replacement strategy is working.
- Humira sales fell 55.7% in the most recent quarter due to biosimilar competition.
- Skyrizi and Rinvoq recorded combined sales growth of more than 40%.
- These newer drugs have helped stabilize AbbVie’s overall revenue base.
If management delivers a strong 2026 outlook on the February call, it would help explain the massive volume of call options now in play. Traders seem to be betting that AbbVie’s growth drivers will continue to outperform, producing another beat-and-raise outcome.
The $100 Billion Pledge
Strategic growth and a new regulatory agreement are also supporting bullish sentiment. On Jan. 12, 2026, AbbVie reached a voluntary agreement with the federal administrationcovering a three-year period. The pact reduces several political risks that have weighed on drug companies. Under the deal, AbbVie committed to a $100 billion investment in U.S. research, development, and manufacturing over the next 10 years. In return, the company secured a three-year exemption from new tariffs and federal drug-pricing mandates—providing institutions with the policy certainty they need to make large investments.
This regulatory win comes as AbbVie moves into the high-growth obesity market. On Jan. 15, 2026, the company announced it had completed its first human trial for GUB014295, a long-acting amylin analog designed to treat obesity—one of the fastest-growing sectors in healthcare.
Entry into this market could drive multiple expansion, meaning investors might be willing to pay more for each dollar of earnings as AbbVie competes in a higher-growth category. The company is also awaiting an FDA decision on its Parkinson’s disease candidate, Tavapadon, in the first half of 2026. These clinical milestones are likely among the catalysts options traders are trying to get ahead of.
Dividend King Status: 53 Years of Reliable Growth
While new growth projects could lift the stock, AbbVie’s fundamentals provide a strong safety net. AbbVie’s analyst community currently holds a Moderate Buy consensus. The average 12-month price target is $247.84, implying roughly 14% upside from the current price. The stock’s forward price-to-earnings ratio (P/E) of about 17.6 looks attractive, particularly as higher-growth drugs contribute more to earnings.
Income investors also find comfort in AbbVie’s Dividend King status. The company has raised its dividend for 53 consecutive years. The current quarterly payout is $1.73 per share, yielding roughly 3.19% and equating to an annual dividend of $6.93. Large institutions own 70.23% of the company, indicating strong demand for its reliable income and defensive qualities. That level of institutional ownership can help establish a valuation floor and reduce the likelihood of a sharp drop while investors await the next catalyst.
Positioning for a Breakout: The Road to $250
The sudden 2,599% surge in call option volume is a clear signal that sophisticated investors are preparing for a breakout. This activity reflects a convergence of positive developments: a more stable regulatory backdrop, a major push into the obesity market, and consistent earnings momentum. AbbVie appears to have moved beyond heavy reliance on legacy drugs and is building a more diversified franchise in immunology and metabolic health.
For investors seeking a blend of dependable income and upside potential, the current market signals are notable. The smart money is positioning for AbbVie, and the upcoming February earnings report could be the catalyst that starts the next leg of a rally.
Thank you for subscribing to Insider Trades Daily, which covers the most recent insider buying and selling activity from Wall Street CEO’s, CFO’s, COO’s and other insiders.
This email is a sponsored message from Golden Portfolio, a third-party advertiser of InsiderTrades.com and MarketBeat.
If you need assistance with your newsletter, please feel free to contact our South Dakota based support team at contact@marketbeat.com.
If you no longer wish to receive email from InsiderTrades.com, you can unsubscribe.
© 2006-2026 MarketBeat Media, LLC. All rights reserved.
345 North Reid Place, Suite 620, Sioux Falls, S.D. 57103. U.S.A..
Featured Link: BlackRock’s $91B secret (From Decentralized Masters)
